SCD

Novo Nordisk has reached an agreement to acquire Forma Therapeutics for $1.1 billion. A key therapeutic Novo Nordisk will acquire with the purchase is etavopivat, Forma’s drug candidate for sickle cell disease (SCD). The drug is being developed to help treat the anemia and damage to red blood cells caused by the genetic disorder, which affects 17 million people globally.